Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>This is our first report on Roivant.</li><li>The company's Q3 2023 earnings were decent and the neutral positives can be highlighted from the continuous growth of VTAMA, ROIV's best-selling branded topical in psoriasis, recording over 300,000 prescriptions and revenues of $20.7 million.</li><li>Additionally, the pipeline for Roivant has compelling developments, with brepocitinib showing promising potential in orphan rheumatology.</li></ul>

This is our first report on Roivant.The company's Q3 2023 earnings were decent and the neutral positives can be highlighted from the continuous growth of VTAMA, ROIV's best-selling branded topical in psoriasis, recording over 300,000 prescriptions and revenues of $20.7 million.Additionally, the pipeline for Roivant has compelling developments, with brepocitinib showing promising potential in orphan rheumatology.

Roivant Sciences Ltd.: Initiation Of Coverage - Acquisition Of New Programs To Diversify In Biosciences! - Major Drivers

External reports (aggregated public sources), Value Investors Club

Value Investors Club

External reports (aggregated public sources)

Key points (machine generated)<ul><li>Roivant Sciences is set to close a $7.25 billion deal with Roche for Telavant, bringing their total value to $12 billion.</li><li>Despite the negative sentiment in the biotech industry, ROIV shares have the potential for over 100% upside with minimal downside, making it an attractive investment opportunity.</li><li>ROIV is likely to return capital to shareholders, benefiting existing holders such as Softbank and Sumitomo.</li></ul>This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Key points (machine generated)Roivant Sciences is set to close a $7.25 billion deal with Roche for Telavant, bringing their total value to $12 billion.Despite the negative sentiment in the biotech industry, ROIV shares have the potential for over 100% upside with minimal downside, making it an attractive investment opportunity.ROIV is likely to return capital to shareholders, benefiting existing holders such as Softbank and Sumitomo.This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Roivant Sciences Ltd (ROIV) - Wednesday, Dec 13, 2023

Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Korea/Asia, Events, IPOs

Event-Driven

<ul>
<li>On 22 March, SillaJen Inc (215600 KS) announced that it will conduct a rights offering worth about 129 billion won for R&amp;D and financials improvement.  </li>
<li>The rights offering size is 34.5 million shares, representing 34% of total outstanding shares. The expected rights offering price is 3,750 won which is 26% lower than current price. </li>
<li>We would not subscribe to this rights offering and we remain negative on the company.</li>
</ul>


On 22 March, SillaJen Inc (215600 KS) announced that it will conduct a rights offering worth about 129 billion won for R&amp;D and financials improvement.  
The rights offering size is 34.5 million shares, representing 34% of total outstanding shares. The expected rights offering price is 3,750 won which is 26% lower than current price. 
We would not subscribe to this rights offering and we remain negative on the company.


SillaJen Rights Offering Worth 34% of Outstanding Shares

Telco/Internet specialist

Kirk Boodry

Redex Research

<ul>
<li>PayTM shares fell 27% in their debut as investors seem unhappy with loss-making companies.  Policy Bazaar's Monday listing was better (+40%) but it's not a good sign for Oyo</li>
<li>This is the seventh Q3 listing event for Vision Fund after little activity in Q2 and is consistent with weak performance for 2021 IPOs in general</li>
<li>The buyback is doing its job with shares up 13% in two weeks with the discount moving from 48%to 43%.  We have updated our Softbank and VF tables below</li>
</ul>


PayTM shares fell 27% in their debut as investors seem unhappy with loss-making companies.  Policy Bazaar's Monday listing was better (+40%) but it's not a good sign for Oyo
This is the seventh Q3 listing event for Vision Fund after little activity in Q2 and is consistent with weak performance for 2021 IPOs in general
The buyback is doing its job with shares up 13% in two weeks with the discount moving from 48%to 43%.  We have updated our Softbank and VF tables below


Softbank Group Mixed Early Results for Indian IPOs

United States

Roivant Sciences Ltd. operates as a healthcare company. The Company offers investigational drugs in development for therapeutic areas such as dermatology, immunology, and respiratory diseases, as well as provides healthcare technologies which help healthcare institutions share and aggregate data. Roivant Sciences provides services worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Roivant Sciences Ltd (ROIV US)

Roivant Sciences Ltd.: Initiation Of Coverage - Acquisition Of New Programs To Diversify In Biosciences! - Major Drivers

This is our first report on Roivant. The company's Q3 2023 earnings were decent and the neutral positives can be highlighted from the continuous...

Baptista Research

Roivant Sciences Ltd (ROIV) - Wednesday, Dec 13, 2023

Roivant Sciences is finalizing a deal with Roche for their company Telavant for $7.25 billion, which would bring their total value to $12, despite...

Value Investors Club

SillaJen Rights Offering Worth 34% of Outstanding Shares

On 22 March, SillaJen announced that it will conduct a rights offering worth about 129 billion. The rights offering size is 34.5 million shares,...

Douglas Kim

Softbank Group Mixed Early Results for Indian IPOs

PayTM has fallen 27% on its debut and whilst Policy Bazaar's Monday listing was better (+40%) it's not a good sign for the upcoming Oyo IPO. We...

Kirk Boodry

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)